New drugs reducing diabetes mortality

Complications of cardiovascular disease activated by type 2 diabetes kills half of the patients. And after the age of 65 the odds go up to 70%.

In 2016 two new medications were introduced and they began significantly reducing the mortality rates.

Empagliflozin causes sugar in the blood to be excreted by the kidneys and eliminated in urine and modifies the progression of heart disease.

The other drug is Liraglutide and was developed by Novo Nordisk for the treatment of type 2 diabetes. It was introduced to the U.S. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one additional weight-related condition. It has a comprehensive effect on many organs.

Given these positive results, it is predicted that we will soon see a complete shift in the lineup of medicines prescribed for diabetes patients.